Conclusions
Mantle cell lymphoma is a protean disease with both indolent and highly aggressive presentations that must be reconciled with host factors, including patient age and comorbid conditions, to appropriately tailor therapy. Although increases in treatment intensity and duration have yielded significant benefit for many with this disease, mantle cell lymphoma continues to be characterized by a pattern of continuous relapse. Novel approaches are showing promise in these settings, with many agents currently poised to make significant additional impact.